Everything below concerns melanocortin receptor. We keep the language plain, cite what the science says, and separate well-supported claims from open questions.
Last reviewed on 2025-10-31. Where a claim depends on a specific study, the study is described rather than over-claimed.
Melanotan-2, also written Melanotan II, is a synthetic cyclic heptapeptide designed as an analogue of alpha-melanocyte-stimulating hormone. Its sequence is Ac-Nle-cyclo[Asp-His-D-Phe-Arg-Trp-Lys]-NH2, and the lactam bridge between the aspartate and lysine side chains constrains the peptide into a ring. This structural change increases receptor affinity and metabolic stability relative to the native hormone. The compound was created in the 1980s as a research tool for studying pigmentation biology.
Melanocytes are the pigment-producing cells of the skin, and they carry melanocortin-1 receptors on their surface. When the receptor is activated, cyclic adenosine monophosphate rises inside the cell and raises the activity of enzymes such as tyrosinase, which increases melanin output. Melanotan-2 binds melanocortin-1 receptors in vitro and in animal models, and this binding is generally described as the basis for the tanning effect. Other receptors account for different effects: melanocortin-4 receptors contribute to appetite and erectile signalling, while melanocortin-3 and melanocortin-5 receptors contribute to energy balance and exocrine function.
Early published reports described melanotan-2 as a tanning agent without sun protection, which means darkening is not the same as protection against ultraviolet radiation. Later studies explored the peptide in erectile dysfunction, hemorrhagic shock, and some skin conditions. No regulator in the United States or Europe has approved it for clinical use. Many products labelled melanotan-2 are sold without approval and their identity and purity are unverified. Its long-term safety in humans remains an open question.
Quality assessment of research-grade peptide rests mainly on reversed-phase high-performance liquid chromatography for purity and on mass spectrometry for identity confirmation. A single main peak above a stated threshold, commonly ninety-eight percent by peak area, is the usual release criterion applied by suppliers. Independent analyses commissioned by laboratories and consumer organisations have repeatedly reported discrepancies between label claims and measured content, including truncated sequences, residual trifluoroacetate, and lower-than-declared peptide mass. Those findings do not establish that every supplier is unreliable, but they indicate that purity figures printed on a vial are claims requiring verification rather than settled facts.
Regulatory treatment varies by jurisdiction and has changed over time. In several countries the peptide is handled as an unapproved prescription medicine, and import or sale for human use is restricted, while elsewhere it falls under poisons or controlled-substance schedules. Enforcement activity against online vendors has been reported in Australia, New Zealand, the United Kingdom and the United States. Scholarly writing discusses melanotan-2 chiefly as an experimental tool and as a case study in unregulated peptide supply, and its precise legal position in any given country should be checked against current national schedules.
Lyophilised melanotan-2 is comparatively robust when kept dry, cold and dark, and a desiccated powder stored at minus twenty degrees Celsius or below is generally expected to retain its chemical integrity for extended periods. In solution the peptide is far less stable, with degradation proceeding through oxidation of tryptophan and histidine residues, hydrolysis adjacent to the lactam bridge, and aggregation at higher concentrations. Repeated freeze-thaw cycling accelerates loss of the parent peak. Working aliquots are therefore prepared once, held cold, and used without letting the stock return to ambient temperature.
| Property | Value | Notes |
|---|---|---|
| Compound class | Synthetic cyclic heptapeptide | Alpha-MSH analogue containing a D-phenylalanine residue |
| Molecular formula | C50H69N15O9 | Average molecular mass approximately 1024.2 g/mol |
| Appearance | White to off-white lyophilised powder | Normally supplied as a freeze-dried solid in a sealed vial |
| Solubility | Freely soluble in water and polar solvents | Dissolves readily in aqueous buffers and in alcohol-water mixtures |
| Receptor targets | MC1R, MC3R, MC4R, MC5R | Acts as a non-selective melanocortin receptor agonist |
Structurally, Melanotan-2 retains the core recognition motif of alpha-melanocyte-stimulating hormone while adding a lactam bridge that links two side chains and constrains the molecule into a ring. This modification lowers susceptibility to enzymatic degradation. The compound acts as an agonist at melanocortin receptors, particularly subtypes associated with melanin production. Because the same receptor family influences several physiological processes, researchers note that its activity is not confined to pigmentation alone. Receptor selectivity continues to be examined in published studies.
Melanotan-2 is a synthetic cyclic heptapeptide designed as an analogue of alpha-melanocyte-stimulating hormone, a naturally occurring peptide involved in pigmentation signalling. Its sequence incorporates modified residues that increase potency and extend biological activity relative to the native hormone. The compound binds receptors of the melanocortin family and is examined mainly in laboratory research. It does not occur naturally and exists only as a manufactured chemical entity produced by solid-phase synthesis.
The peptide was developed during the 1980s by researchers investigating melanocortin signalling and skin pigmentation pathways. Early work focused on analogues of alpha-melanocyte-stimulating hormone that would resist enzymatic breakdown more effectively than the parent molecule. Melanotan-2 emerged from that programme as a shortened, cyclised variant. Reports describing its synthesis and receptor activity later appeared in the scientific literature. Commercial availability grew through unregulated channels rather than through pharmaceutical approval.
Lyophilised peptide powder is comparatively stable when kept dry, cold and protected from light. Once dissolved, the molecule is exposed to hydrolysis, oxidation and microbial growth, and degradation accelerates at higher temperatures and in alkaline solution. Repeated freeze-thaw cycles concentrate solutes and promote aggregation. Handling guidance for research peptides commonly clusters around freezer temperatures for powder and short refrigerated use for reconstituted solutions, with pH control and sterile technique applied throughout.
Verification of a purchased sample requires documentation linking a batch to a certificate of analysis, and that document should be read for the methods used rather than the headline purity figure. A single chromatographic percentage does not establish identity. Independent laboratories can perform identity and content assays, but no such test establishes that a product is suitable for human use. Claims about efficacy rest largely on small, early studies rather than on replicated controlled trials, and that gap remains open.
=== Complications === GDM poses a risk to the mother and child. This risk is largely related to uncontrolled blood glucose levels and their consequences. The risk increases with higher blood glucose levels. Treatment resulting in better control of these levels can reduce some of the risks of GDM considerably. Having GDM can lead to mental health issues, with the distress added to the pregnancy. Women with gestational diabetes experienced increased anxiety, depression, and stress. Not only does it affect mental health during pregnancy, but it also leads to an increased risk of postpartum depression. The risk is over 4 times greater than a normal pregnancy. It was found that physical activity could decrease the risk of postpartum depression. It is a form of therapy that can help reduce the stress of these mental health issues. The two main risks GDM imposes on the baby are growth abnormalities and chemical imbalances after birth, which may require admission to a neonatal intensive care unit. Infants born to mothers with GDM are at risk of being both large for gestational age (macrosomic) in unmanaged GDM, and small for gestational age and Intrauterine growth retardation in managed GDM. Macrosomia in turn increases the risk of instrumental deliveries (e.g., forceps, ventouse, and caesarean section) or problems during vaginal delivery (such as shoulder dystocia). Macrosomia may affect 12% of normal women compared to 20% of women with GDM.
The "open" to "closed" transformation between G and F forms and its implications on the relative motion of several key residues and the formation of water wires have been characterized in molecular dynamics and QM/MM simulations.
The 1960s saw extensive research into the synthesis of hydroquinone from acetylene and carbon monoxide via catalytic iron pentacarbonyl. Rhodium or ruthenium can substitute for iron as the catalyst with favorable chemical yields, but are not typically used due to the cost of recovery from the reaction mixture. Hydroquinone and its derivatives can also be prepared by oxidation of various electron-rich benzene derivatives, such as phenols, aniline, and DIPB. Examples include Elbs persulfate oxidation and Dakin oxidation. Hydroquinone was first obtained in 1820 by the French chemists Pelletier and Caventou via the dry distillation of quinic acid. Hydrolysis of chlorophenol. The latter two methods are generally less atom-economical than oxidation with hydrogen peroxide, as are certain industrial implementations of the peroxide oxidation. Their commercial practice in China produced serious pollution in 2022.
==== Stability ==== According to Sassen (1997) the role of hydrates at chemosynthetic communities has been greatly underestimated. The biological alteration of frozen gas hydrates was first discovered during the MMS study entitled "Stability and Change in Gulf of Mexico Chemosynthetic Communities". It is hypothesized that the dynamics of hydrate alteration could play a major role as a mechanism for regulation of the release of hydrocarbon gases to fuel biogeochemical processes and could also play a substantial role in community stability. Recorded bottom-water temperature excursions of several degrees in some areas such as the Bush Hill site (4–5 °C at 500-metre (1,600-foot) depth) are believed to result in dissociation of hydrates, resulting in an increase in gas fluxes (MacDonald et al., 1994). Although not as destructive as the volcanism at vent sites of the mid-ocean ridges, the dynamics of shallow hydrate formation and movement will clearly affect sessile animals that form part of the seepage barrier. There is potential of a catastrophic event where an entire layer of shallow hydrate could break free of the bottom and considerably affect local communities of chemosynthetic fauna. At deeper depths (>1,000 metres (3,300 feet)), the bottom-water temperature is colder (by approximately 3 °C) and undergoes less fluctuation. The formation of more stable and probably-deeper hydrates influences the flux of light hydrocarbon gases to the sediment surface, thus influencing the surface morphology and characteristics of chemosynthetic communities.
Sources: en.wikipedia.org
=== EC 2.1.3: Carboxy- and Carbamoyltransferases === EC 2.1.3.1: methylmalonyl-CoA carboxytransferase EC 2.1.3.2: aspartate carbamoyltransferase EC 2.1.3.3: ornithine carbamoyltransferase EC 2.1.3.4: deleted EC 2.1.3.5: oxamate carbamoyltransferase EC 2.1.3.6: putrescine carbamoyltransferase EC 2.1.3.7: 3-hydroxymethylcephem carbamoyltransferase EC 2.1.3.8: lysine carbamoyltransferase EC 2.1.3.9: N-acetylornithine carbamoyltransferase EC 2.1.3.10: malonyl-S-ACP:biotin-protein carboxyltransferase EC 2.1.3.11: N-succinylornithine carbamoyltransferase EC 2.1.3.13: The enzyme has been replaced by EC 6.1.2.2 EC 2.1.3.14: The enzyme has been replaced by EC 6.1.2.2 EC 2.1.3.15: acetyl-CoA carboxytransferase
Using the money from her portraits, Jolene leaves and boards a bus west out of South Carolina. Jolene resorts to hitchhiking further west, supporting herself by prostitution. Jolene ends up in Arizona, working as a waitress at an outdoor diner. There, she meets Coco Leger, an aspiring musician and tattoo artist. A relationship blossoms between them and Jolene becomes a tattoo artist at Coco's parlor. After two weeks of dating, Jolene moves in with Coco and he convinces her to get married. After he passes out during sex, Coco is revealed to have a cocaine addiction, supporting his habit and the parlor by dealing cocaine. One evening, a young woman enters the parlor and declares herself to be his wife, Marin and introduces their son, Coco Jr. Coco returns and is confronted by both women before he walks out with Marin and the baby. Furious with Coco, Jolene destroys the parlor, dumps the cocaine on a table, steals the drug money and dumps her ring in the center of the cocaine before dialing 911 and fleeing the scene. Jolene later is in Las Vegas, working as an erotic dancer when she meets Sal Fontaine, a mobster. He takes a liking to her and invites her to quit dancing and move into his high rise condo. Jolene enjoys a life of luxury with Sal, going to fancy dinners and exploring her talent as an artist. One night, Sal demands that Jolene get dressed, go downstairs and wait for him. She falls asleep in the restaurant and quietly returns to the condo to find Sal dead and the mob looking for her. Jolene escapes and ends up hitchhiking on a truck to Tulsa.
=== Interchangeability of centipede species in clinical practices === Comparative studies on S. mutilans and S. mojiangica, a common substitute for the former, has found that in pharmacodynamics and toxicology, the two centipede species have similar effects, and is theoretically proved that S. mutilans can be replaced by S. mojiangica. The same study found that two species showed similar results in various fields, including effects on animal haemoglobin and weight, chromosomal aberration tests, anticonvulsive tests, effects on in vitro fungal and bacterial growth, and acute toxicity tests. The study also suggested both centipede species can be used in relatively large doses, as they were both low in acute and genetic toxicities. Although the two centipede species were shown to be interchangeable in clinical practices, their interchangeability in clinical application was again questioned by some researchers, as more recent studies suggested that centipede proteins have a major role in their clinical effects. Through proteomics, researchers had found that the venoms of S. monjiangica and S. mutilans are different in the number of overlapping sequences and precursors for proteins and peptides. In addition, unique precursors were also found in both species for proteins and peptide levels. As the species differ in protein and peptide level, researchers of this study concluded that the interchangeability of centipede species requires further evaluation.
=== Electrolyte === The electrolyte ensures good electrical conductivity and minimizes iR drop such that the recorded potentials correspond to actual potentials. For aqueous solutions, many electrolytes are available, but typical ones are alkali metal salts of perchlorate and nitrate. In nonaqueous solvents, the range of electrolytes is more limited, and a popular choice is tetrabutylammonium hexafluorophosphate.
Serine /ˈsɪəriːn/ (symbol Ser or S) is an α-amino acid that is used in the biosynthesis of proteins. It contains an α-amino group (which is in the protonated −NH+3 form under biological conditions), a carboxyl group (which is in the deprotonated −COO− form under biological conditions), and a side chain consisting of a hydroxymethyl group, classifying it as a polar amino acid. It can be synthesized in the human body under normal physiological circumstances, making it a nonessential amino acid. It is encoded by the codons UCU, UCC, UCA, UCG, AGU and AGC.
Sources: en.wikipedia.org
No. It is a laboratory-made peptide, while the natural hormone is alpha-melanocyte-stimulating hormone, a longer peptide produced by the pituitary gland and by skin cells. Melanotan-2 mimics only a short active region of that hormone and contains non-natural residues such as D-phenylalanine.
No approved regulatory indication exists in major markets. An approval exists for a different peptide, afamelanotide, which is used for a rare photosensitivity disorder called erythropoietic protoporphyria. Melanotan-2 itself remains a research compound with no cleared clinical role.
Melanocortin-1 receptors on melanocytes are the receptor most closely linked to pigment production. The peptide is not selective, however, and also activates melanocortin-3, melanocortin-4, and melanocortin-5 receptors. That lack of selectivity is the usual explanation offered for both its range of observed effects and its off-target effects.
Solutions are best kept cold, protected from light, and buffered to a pH that limits hydrolysis. Dividing a stock into single-use aliquots avoids repeated freeze-thaw cycles, which measurably reduce the intact parent peak over time.